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Abstract
Background: Several trials evaluated the role of ovarian function suppression for the adjuvant treatment of
premenopausal patients with hormone receptor-positive early breast cancer. Based on the results of the SOFT and
TEXT trials, international guidelines recommend the addition of ovarian function suppression to standard adjuvant
endocrine therapy for patients at higher risk of relapse.
Methods: The ERA project (Evaluation of Risk factors in the Adjuvant treatment of breast cancer in premenopausal
patients) was devised with the objective of obtaining a consensus on the identification of risk factors and the use
of ovarian function suppression in the adjuvant treatment of these women. To this aim, a panel of 31 Italian
oncologists with expertise in breast cancer participated in a Delphi consensus study in June 2017.
Results: A total of 29 statements related to prognostic factors, therapeutic strategies and ovarian function
suppression were defined and voted to gain final consensus. For each topic we report data supporting the
acquired consensus and the relevant issues discussed.
Conclusions: The SOFT and TEXT trials have changed the standard adjuvant treatment of premenopausal patients
with hormone receptor-positive early breast cancer, but the available treatment options require a careful risk
assessment and toxicities evaluation to ensure the greatest clinical benefit for each patient.
Keywords: Breast cancer, Premenopausal patients, Adjuvant endocrine therapy, Ovarian function suppression,
LHRHa, Tamoxifen, Aromatase inhibitor
Background
Breast cancer represents the most frequently diagnosed
cancer in premenopausal women, with about 20% of all
breast cancers diagnosed before age 50 [1]. Most of these
tumors are hormone receptors-positive (HR-positive), so
that adjuvant hormonal therapy is usually recommend to
reduce the risk of recurrence after radical surgery [2, 3].
For decades, tamoxifen for 5–10 years has represented the
standard adjuvant endocrine therapy for premenopausal
women with HR-positive early breast cancer (EBC), with a
significant reduction in breast cancer mortality for up to
15 years from diagnosis [4]. Recently, the SOFTand TEXT
trials have revaluated the role of ovarian function suppres-
sion (OFS) in the treatment of these women, combining
luteinizing hormone-releasing hormone analogs (LHRHa)
with tamoxifen or aromatase inhibitors (AIs), and provid-
ing new data for the management of premenopausal
patients with EBC [5–7]. On the basis of these trials, inter-
national guidelines recommend the use of OFS as a com-
ponent of standard endocrine therapy for premenopausal
women at high risk of relapse, pointing out the critical
role of risk assessment for these patients [8–10]. There-
fore, one of the major challenges in choosing the optimal
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adjuvant treatment of premenopausal HR-positive EBC
patients is the identification of reliable prognostic factors
and their contribution in recurrence risk. Indeed, the
absolute benefit of adjuvant treatments depends on the
estimated risk of cancer recurrence [11], thus generating
debate in defining a treatment algorithm for individual
patients since clinical trials mainly focus on treatment effi-
cacy in the general population.
The ERA project (Evaluation of Risk factors in the Ad-
juvant treatment of breast cancer in premenopausal pa-
tients) implemented a Delphi model to gain consensus
on the evaluation of risk factors and the use of OFS in
the adjuvant treatment of premenopausal patients with
ER-positive EBC.
Methods
The Delphi consensus model applied to this study consisted
of three key phases. During the first phase, a Steering Com-
mittee including 10 experts in breast cancer (BC) was asked
to define relevant statements on the topic at hand. After
two advisory boards, the Steering Committee defined 29
preliminary recommendation statements on prognostic fac-
tors, adjuvant endocrine treatment and LHRHa therapy in
premenopausal patients with ER-positive EBC, based on
available published data. In the second phase, a web-based
survey was distributed to a panel of 40 oncologists with
expertise in BC. Overall, 31 recipients completed the online
consensus survey (hereinafter referred to as the expert
panel). The panellists were asked to express anonymously
their level of agreement with each statement, using a five
point Likert scale (where 1 = completely disagree; 2 = slightly
disagree; 3 = partially agree; 4 = agree; 5 = completely agree)
[12]. A consensus was deemed as achieved if either the sum
of answers 1 and 2 (negative), or 3, 4 and 5 (positive)
exceeded 66%, as described in previous studies conducted
with this method [13, 14]. The third phase was held during
a consensus conference in Rome on 19 June 2017. The ex-
pert panel (31 members) and the Steering Committee (10
members) were invited to discuss in public sessions the
results of the online consensus survey and voted again for
those statements with partial consensus (mainly level 3
agreement) or negative consensus. Of the 41 members, 21
took part in the final meeting.
Results
During the consensus conference, 27 statements met a
positive consensus, whereas 2 statements did not reach
the threshold for positive agreement. An additional state-
ment was defined during the third phase and gained posi-
tive consensus after the vote of the panellists. Overall, 28
statements reached a positive consensus (Table 1) and
were clustered in five conclusive highlights (1–5) related
to 3 main topics: prognostic groups, therapeutic strategy
and ovarian function suppression. For each topic we
report data supporting the acquired consensus and rele-
vant issues discussed by the panellists, including reasons
for negative consensus if occurred.
Prognostic groups
The risk of recurrence in premenopausal women with HR-
positive EBC depends on prognostic factors
A number of tumor- and patient-related characteristics have
been found relevant in predicting the risk of recurrence or
death from EBC. Eight prognostic factors were reviewed
and individually voted by the panellists. High level of agree-
ment was observed during the discussion, with seven out of
eight statements meeting a positive consensus with more
than 94% positive agreement according to the pre-specified
criteria (Table 1). As discussed by the panellists, traditional
prognostic factors include axillary nodes involvement [15]
and tumor size [16, 17]. Tumor grade [18–20], and prolifer-
ative markers (e.g. Ki-67 expression assessed by immuno-
staining) [21, 22] provide additional prognostic information
and should be routinely considered for risk assessment.
However, the lack of a reliable cut-off point for Ki-67 evalu-
ation and its low inter-laboratory reproducibility were con-
sidered relevant issues by the panellists, suggesting as a
better reference the median value of the local laboratory
[23–25]. Additional biological features, including the expres-
sion levels of estrogen-receptor (ER), progesterone-receptor
(PgR) and the overexpression of the human epidermal
growth factor receptor 2 (HER2) are both prognostic and
predictive in EBC [26–32]. On this latter topic, the prognos-
tic relevance of HER2 overexpression, biologically associated
with increased tumor aggressiveness and higher rates of re-
currence, has radically changed with the use of adjuvant
anti-HER2 targeted therapies, insuring improved outcomes
even when compared with luminal lower-stage tumors [33,
34]. Taking into account the ER/PgR expression levels, re-
cent data suggest that BC with ER expression inferior to
10% are more similar to triple-negative breast cancer
(TNBC) than luminal disease, with worse survival outcomes
and limited advantage from adjuvant endocrine therapy
[35]. Additionally, ER-positive/PgR-negative tumors seem to
present worse outcomes compared to ER/PgR-positive EBC
[36]. This data suggest that low levels of expression of both
ER and PgR may indicate a more aggressive biology and a
lower likelihood of benefit from adjuvant endocrine treat-
ment. Nevertheless, a 1% cut-off is still recommended for
estrogen receptor positivity by the American Society of
Clinical Oncology (ASCO)/College of American Patholo-
gists (CAP) guidelines [37].
Histological assessments are often used as surrogate to
define BC molecular subtypes in clinical practice. In this re-
gard, multigene assays such as Oncotype DX™ and Mam-
maPrint® (a 21-gene recurrence score and a 70-gene
signature, respectively) are considered to add prognostic in-
formation, particularly for avoiding adjuvant chemotherapy
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Table 1 Delphi model results
Topic Statement Level of agreement/disagreement Positive
ConsensusaCompletely
disagree
Slightly
disagree
Partially
agree
Agree Completely
agree
Prognostic groups 1. The risk of recurrence in premenopausal
women with HR-positive EBC depends on
prognostic factors.
The following prognostic factors should be
considered for risk assessment:
A. Tumor stage (T and N) 0% 0% 10% 32% 58% 100%
B. Tumor grade 0% 0% 16% 39% 45% 100%
C. HER2 overexpression 0% 0% 0% 23% 77% 100%
D. Age 3% 3% 39% 32% 23% 94%
E. Gene expression profile 0% 3% 39% 42% 16% 97%
F. Ki-67 0% 0% 10% 39% 51% 100%
G. ER and PgR expression levels 0% 3% 7% 35% 55% 97%
H. Histology (ductal vs. lobular) 38% 52% 5% 0% 5% 10%
2. Predictive and prognostic factors guide
the choice of adjuvant endocrine
treatment in premenopausal women with
HR-positive EBC.
The following factors guide the choice of
treatment in premenopausal patients who
are candidates for adjuvant endocrine
therapy:
A. Tumor stage (T and N) 0% 6% 20% 29% 45% 94%
B. Tumor grade 3% 7% 16% 52% 22% 90%
C. HER2 overexpression 0% 10% 12% 39% 39% 90%
D. Age 0% 10% 19% 39% 32% 90%
E. Gene expression profile 0% 13% 32% 42% 13% 87%
F. Ki-67 0% 3% 23% 39% 35% 97%
G. ER and PgR expression levels 0% 3% 6% 39% 52% 97%
H. Histology (ductal vs. lobular) 33% 52% 5% 0% 10% 15%
Therapeutic
strategy
3. For premenopausal women with HR-
positive EBC at low risk of recurrence,
adjuvant tamoxifen is the recommended
adjuvant treatment.
A. The addition of OFS to tamoxifen or
exemestane did not show clinical benefit
in terms of DFS, DDFS, BCFI and OS in
low–risk patients.
6% 10% 13% 45% 26% 84%
B. The addition of OFS to standard
endocrine therapy could be associated
with worse adverse effects, according to
patients’ age.
3% 10% 32% 36% 19% 87%
C. If tamoxifen is contraindicated, OFS
with or without exemestane should be
considered.
0% 0% 6% 42% 52% 100%
4. The addition of OFS to standard
adjuvant endocrine therapy is
recommended for premenopausal women
with HR–positive EBC at intermediate or
high risk of recurrence.
A. The addition of OFS to tamoxifen
reduces the risk of breast cancer
recurrence.
0% 3% 13% 52% 32% 97%
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at low risk women, when proliferative markers do not pro-
vide conclusive clues even if matched with classic
clinico-pathological factors [38–40]. Of note, the eighth edi-
tion of the primary Tumor, lymph Node, and Metastasis
(TNM) classification of the American Joint Commission on
Cancer (AJCC) incorporated biologic prognostic and pre-
dictive factors (tumor grade, HR and HER2 expression,
multigene assays) into EBC staging [41]. In this respect, the
panel endorsed the use of the eighth AJCC classification in
clinical practice starting from January 2018, since it offers
more accurate prognostic information. Prospective valid-
ation data for EBC patients were published after this con-
sensus study and confirmed 29.5% of patients upstaged and
28.1% downstaged with the new AJCC classification [42].
Considering patient-related factors, younger age has
been associated with worse outcome in HR-positive EBC
[43], probably due to suboptimal estrogen inhibition, less
therapeutic adherence, and differences in tumor biology.
However, as widely discussed by the panellists, younger
patients should not be considered high-risk per se, but
age should be evaluated with other prognostic factors
during risk assessment.
A negative consensus was reached when considering
the prognostic relevance of tumor histology (ductal vs.
lobular) in HR-positive EBC patients (38% completely
disagree, 52% slightly disagree). As argued by the panel-
lists, lobular breast cancer typically presents with good
prognostic features (G1–2, low Ki-67, HR-positive and
Table 1 Delphi model results (Continued)
Topic Statement Level of agreement/disagreement Positive
ConsensusaCompletely
disagree
Slightly
disagree
Partially
agree
Agree Completely
agree
B. OFS plus exemestane reduced the risk
of breast cancer recurrence compared to
OFS plus tamoxifen.
0% 0% 23% 45% 32% 100%
C. OFS plus exemestane reduced the risk
of breast cancer recurrence compared to
tamoxifen alone.
0% 3% 6% 52% 39% 97%
D. The combination of OFS and
tamoxifen may be an alternative to OFS
plus AIs for patients at intermediate risk of
breast cancer recurrence.
0% 3% 45% 32% 20% 97%
Ovarian function
suppression
5. The standard duration of adjuvant OFS
for premenopausal women with HR-
positive EBC is 5 years, with LHRHa therapy
administered on a monthly basis.
A. Available data on OFS come from
clinical trials in which LHRHa therapy was
administered on a monthly basis.
0% 0% 6% 55% 39% 100%
B. Adjuvant endocrine treatment with
LHRHa therapy plus AIs may result in
incomplete ovarian suppression.
0% 26% 16% 32% 26% 74%
C. Potential predictive factors for
suboptimal ovarian suppression are high
BMI, no prior chemotherapy, low baseline
FSH and LH levels.
0% 13% 23% 45% 19% 87%
D. Surgical oophorectomy could be an
alternative to LHRHa therapy, according to
patients’ preferences.
3% 7% 16% 39% 35% 90%
E. LHRHa therapy should start preferably
on the second day of the menstrual cycle.
0% 19% 13% 42% 26% 81%
F. AIs should be administered at least
4 weeks after the first dose of LHRHa
therapy, when associated with OFS.
0% 4% 32% 32% 32% 96%
G. Perimenopausal patients with
chemotherapy-induced amenorrhea should
receive OFS if baseline FSH and E2 levels
are not in the postmenopausal range.
6% 6% 0% 28% 60% 88%
Abbreviations: HR hormone receptors, EBC early breast cancer, HER2 Human epidermal growth factor receptor 2, ER estrogen receptor, PgR progesterone receptor,
OFS, ovarian function suppression, DFS disease-free survival, DDFS distant disease-free survival, BCFI breast cancer-free interval, OS overall survival, AIs aromatase
inhibitors, LHRHa luteinizing hormone-releasing hormone analogs, BMI body mass index, FSH follicle-stimulating hormone, LH luteinizing hormone,
E2 beta-2-estradiol
aA consensus was deemed as achieved if either the sum of answers 1 and 2 (negative), or 3, 4 and 5 (positive) exceeded 66%
Pelizzari et al. BMC Cancer  (2018) 18:932 Page 4 of 11
usually HER2-negative) [44], but no clear prognostic ad-
vantage has been ever shown, with some contrasting evi-
dence on long-term outcomes [44, 45].
In conclusion, the panellists established that the fol-
lowing prognostic factors should be considered for risk
assessment:
A. Tumor stage (T and N)
B. Tumor grade
C. HER2 overexpression
D. Age
E. Gene expression profile
F. Ki-67
G. ER and PgR expression levels
The seven above-mentioned prognostic factors were
considered as independent statements and separately
voted. An additional element, histology (ductal vs. lobu-
lar), did not reach the positive consensus and was ex-
cluded from the list (Table 1).
Predictive and prognostic factors guide the choice of
adjuvant endocrine treatment in premenopausal women
with HR-positive EBC
After the identification of significant prognostic factors in
premenopausal women with HR-positive EBC, panel
members were asked about the clinical relevance of these
elements in guiding the therapeutic choices. There are dif-
ferent aspects to consider when assessing this issue, in-
cluding a missing agreement on the threshold for
recommending adjuvant chemotherapy, and a variable
magnitude of benefit deriving from different endocrine
therapies. The statements discussed below focused on
which prognostic factors should be considered for adju-
vant treatment choice, stratifying patients for high-risk
and low-risk features, without defining a specific clinical
setting of applicability. In this respect, the panellists did
not define any particular combination of these factors to
give indications about low or high-risk definition, since
specific clinical considerations need to be discussed on a
case-by-case basis. Particular clinical scenarios will be
reviewed further on. All the prognostic items selected
above were confirmed relevant for treatment choice, with
a slightly inferior but still solid overall agreement among
the panellists (more than 87% positive agreement accord-
ing to the pre-specified criteria; see Table 1).
During the public discussion, the panel addressed some
open questions on factors predicting adjuvant endocrine
treatment benefit. Firstly, as previously discussed, inter-
national guidelines are not concordant on a common
threshold for HR positivity (ER/PgR expression > 1% vs. >
10%) [37, 38]. Secondly, considering HER2-positive luminal
BC, the panellists warned about possible crosstalk between
the estrogen receptor and HER2 pathways, with conflicting
evidences referring on a potential detrimental effect of tam-
oxifen in triple-positive BC [46–48]. Prospective data are
too limited to draw final considerations, although some
panellists prudentially assumed that the use of tamoxifen as
the sole adjuvant therapy might not be appropriate for pre-
menopausal patients with HER2-positive luminal BC. Fi-
nally, the panel commented on the positive consensus
reached over the use of genomic assays to tailor adjuvant
treatments for premenopausal patients (13% slightly dis-
agree, 32% partially agree, 55% agree/completely agree).
Clinical validation of these assays is becoming reliable, sup-
porting their use in clinical practice, particularly to avoid
chemotherapy for patients with node-negative luminal EBC
[39, 40]. The elevated prevalence of partial agreement with
this statement was mainly explained by the limited use of
these assays in some Italian centres, and negative or weak
recommendations for their use for very low–risk or node–
positive patients with luminal EBC [38, 49].
The panellist concluded that the following factors
should guide the choice of treatment in premenopausal
patients who are candidates for adjuvant endocrine
therapy:
A. Tumor stage (T and N)
B. Tumor grade
C. HER2 overexpression
D. Age
E. Gene expression profile
F. Ki-67
G. ER and PgR expression levels
The seven above-mentioned factors were considered as
independent statements and separately voted (Table 1).
An eighth element, histology (ductal vs. lobular), did not
reach the positive consensus and was excluded from the
list (33% completely disagree, 52% slightly disagree).
Therapeutic strategy
For premenopausal women with HR-positive EBC at low risk
of recurrence, adjuvant tamoxifen is the recommended
adjuvant treatment
The first clinical issue addressed by the panellists was to
define the best adjuvant endocrine therapy for low-risk
premenopausal patients with HR-positive EBC. To gain
consensus on the best therapeutic strategy for these
women, three statements were discussed and voted
(A-C, see Table 1). Each statement will be separately
reviewed for a better comprehension of the panel debate
on the available evidences:
A. The addition of OFS to tamoxifen or exemestane did
not show clinical benefit in terms of disease-free sur-
vival (DFS), distant disease-free survival (DDFS),
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breast cancer-free interval (BCFI) and overall sur-
vival (OS) in low-risk patients
Several studies have tried to provide evidences for the use
of OFS alone or in addition to standard adjuvant therapies,
including chemotherapy and tamoxifen, without drawing
definitive results [50–52]. Two randomized phase III trials
have further examined the combination of OFS with stand-
ard adjuvant tamoxifen. The E-3193 INT-0142 trial enrolled
345 low-risk premenopausal women with HR-positive EBC
(83% pT1, pN0, median age 45 years, no adjuvant chemo-
therapy allowed) and no benefit was shown with the
addition of OFS to tamoxifen (DFS HR: 1.17; 95% CI, 0.64–
2.12; p= .62; OS HR: 1.19; 95% CI 0.52–2.70; p= .67) [53].
Similarly, the SOFT trial randomized 3066 premenopausal
patients to receive 5 years of adjuvant tamoxifen, OFS plus
tamoxifen, or OFS plus exemestane. The primary analysis
aimed at comparing the benefit of OFS plus tamoxifen with
adjuvant tamoxifen alone. With a median follow-up of
5.6 years, no advantage was observed on DFS (HR: 0.83;
95% CI 0.66–1.04; p= .10), DDFS (HR: 0.88; 95% CI, 0.66–
1.18; p= .40), BCFI (HR: 0.81; 95% CI, 0.63–1.03; p= .09),
and OS (HR: 0.74; 95% CI, 0.51–1.09; p= .13), especially for
low-risk patients (no adjuvant chemotherapy, tumor ≤2 cm,
axillary node negative), who showed a 5-year DFS rate
higher than 95% with adjuvant tamoxifen alone [5]. There-
fore, the panel concluded that tamoxifen should be still
considered the standard of care for HR-positive EBC with a
low risk of recurrence according to SOFT data. An update
analysis after a median follow-up of 8 years was presented
subsequently this consensus study, showing a significant
benefit on DFS (HR: 0.76; 95% CI, 0.62–0.93; p= .009), BCFI
(HR: 0.76; 95% CI, 0.61–0.95; p= 0.01) and OS (HR: 0.67;
95% CI, 0.48–0.92; p= .01) but not on DDFS (HR: 0.86; 95%
CI, 0.66–1.13; p= .28) with the addition of OFS to tamoxifen
in the entire trial population. Although no influence on rela-
tive treatment effects was seen according to chemotherapy
prescription, more than 97% of patients in SOFT who did
not receive chemotherapy were still free of distant recurrent
and alive at 8 years regardless the treatment group. Further-
more, in subgroup analyses a non-significant differ-
ence on DFS (HR: 0.76; 95% CI, 0.52–1.12), DDFS
(HR: 1.09; 95% CI, 0.46–2.57), BCFI (HR: 0.83; 95%
CI, 0.52–1.32), and OS (HR: 1.96; 95% CI, 0.67–5.73)
was detected in this low-risk cohort for OFS plus
tamoxifen rather than tamoxifen alone [7]. In conclu-
sion, according to these data, tamoxifen alone may
still represent a reasonable adjuvant therapeutic
option for patients with low-risk clinico-pathological
features and HR-positive EBC.
B. The addition of OFS to standardendocrine therapy
could be associated with worse adverse effects,
according to patients’ age
In the SOFT trial, an increment of severe or
life-threatening and disabling adverse events (31.3% vs.
23.7%) was observed with the addition of OFS to tam-
oxifen. Patients experienced worse endocrine-related
symptoms such as hot flushes, musculoskeletal disor-
ders, sweating, sleep disturbance, vaginal dryness and
loss of sexual interest, particularly during the first 2 years
of treatment [5, 54]. Moreover, according to TEXT data,
sexual dysfunctions (vaginal dryness, decreased libido,
dyspareunia) were more frequent when adding OFS to
exemestane rather than tamoxifen, together with a
higher incidence of musculoskeletal symptoms among
which osteoporosis (13.2% vs. 6.4%) and fractures (6.8%
vs. 5.2%) [6]. Lastly, the addition of OFS did not seem to
affect global cognitive function after 1 year of treatment
[55]. The risk of bone loss and osteoporosis represents a
relevant concern for premenopausal women candidate
to OFS, thus every patient should receive at least a base-
line bone assessment and vitamin-D supplementation if
needed. Therefore, the decision on the optimal adjuvant
endocrine therapy should always consider treatment tox-
icities, which must be discussed with patients according
to their preferences and comorbidities, even during the
adjuvant treatment.
C. If tamoxifen is contraindicated, OFS with or without
exemestane should be considered
For patients candidate for adjuvant endocrine therapy
who are not eligible to tamoxifen (e.g. for contraindica-
tions or severe side effects), a reasonable option is the
use of OFS with or without exemestane according to the
risk of recurrence.
The addition of OFS to standard adjuvant endocrine
therapy is recommended for premenopausal women with
HR-positive EBC at intermediate or high risk of recurrence
The panellists were asked to focus on the use of OFS in
patients at intermediate or high risk of recurrence. To
untangle this topic, they reviewed the SOFT and TEXT
data and obtained positive consensus over the following
four statements (A-D; see Table 1). High level of agree-
ment was observed during the discussion, with all the
statements meeting a positive consensus with more than
97% positive agreement according to the pre-specified
criteria (Table 1):
A. The addition of OFS to tamoxifen reduces the risk of
breast cancer recurrence
Considering the pre-planned subgroup analysis of the
SOFT trial, with a median follow-up of 5.6 years, improved
outcomes were observed with the addition of OFS to
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tamoxifen among high-risk patients who received adjuvant
chemotherapy and remained premenopausal at the end of
treatment (3.6% absolute improvement in 5-year DFS rate,
HR: 0.82, 95% CI, 0.64–1.07, p = .96; 3.6% absolute im-
provement in 5-year OS rate, HR: 0.64; 95% CI, 0.42–0.96;
p = .03) and in HER2 positive tumors (12.4% absolute im-
provement in 5-year DFS rate, HR 0.42; 95% CI, 0.22–0.80;
p = .04). After correction for prognostic factors, the com-
bination of OFS plus tamoxifen was associated with a re-
duced hazard of recurrence, second invasive cancer, or
death as compared to tamoxifen alone (HR: 0.78; 95% CI,
0.62–0.98; p = .03) [5]. Taking into consideration these re-
sults, the panellists agreed with the statement that the
addition of ovarian suppression to tamoxifen is associated
with reduced risk of breast cancer recurrence in patients at
intermediate or high risk of recurrence (e.g. patients war-
ranting adjuvant chemotherapy who remain premeno-
pausal afterward). After the conclusion of this Delphi
consensus study, an update of the SOFT trial with ex-
tended follow-up was presented. A 4.2% absolute gain in
8-year DFS rate (83.2% vs. 78.9%; HR: 0.76; 95% CI, 0.62–
0.93, p = .009) and a 1.8% absolute gain in 8-year OS rate
(93.3% vs 91.5%; HR: 0.67; 95% CI, 0.48–0.92; p = .01)
were seen among patients receiving OFS plus tamoxifen
rather than tamoxifen alone. The benefit of OFS addition
was even higher for those patients who had received adju-
vant chemotherapy (5.3% absolute improvement in 8-year
DFS rate, HR: 0.76, 95% CI, 0.60–0.97; 4.3% absolute im-
provement in 8-year OS rate, HR: 0.59; 95% CI, 0.42–
0.84), confirming the recommendation expressed by the
consensus panel [7].
This is also concordant with a recent meta-analysis in-
cluding data from about 6000 premenopausal patients
treated with tamoxifen with or without OFS, in which the
addition of OFS after adjuvant chemotherapy significantly
improved OS, with a 24% mortality reduction (p = .03) [52].
B. OFS plus exemestane reduced the risk of breast
cancer recurrence compared to OFS plus tamoxifen
The joint analysis of the SOFT and TEXT trials collected
data from 4690 patients coming from both the studies to
compare the use of OFS in association with tamoxifen or
exemestane in premenopausal women with HR-positive
EBC. After a median follow up of 68 months, a 3.8% gain in
terms of 5-year DFS rate was observed among patients
randomized to OFS plus exemestane rather than OFS plus
tamoxifen (91.1% vs. 87.3%, HR 0.72, 95% CI, 0.60–0.85, p
< .001), with a significantly higher 5-year BCFI rate (92.8%
vs. 88.8%, HR 0.66, 95% CI, 0.55–0.80, p < .001) and 5-year
DDFS rate (93.8% vs. 92%, HR 0.78, 95% CI, 0.62–0.97 p
= .02), but no difference in OS was observed [6]. Interest-
ingly, the authors were able to quantify the absolute treat-
ment effect in both SOFT and TEXT trials with the
adoption of a composite risk score based on prognostic
clinico-pathological characteristics: an improvement ranging
from 10 to 15% of the 5-year BCFI rate was observed with
the combination of exemestane plus OFS compared with
tamoxifen plus OFS or tamoxifen alone for patients at high
risk of recurrence (age < 35, grade 2–3 tumors, high Ki-67,
> 4 nodes involved, adjuvant chemotherapy), but a lower or
minimal benefit was seen for patients at intermediate or
minimal risk (5% and < 3%, respectively) [11].
These data were confirmed by the updated analysis of
the SOFT and TEXT trials performed after 9 years of
median follow-up, published after the consensus ac-
quired in this study. The use of OFS plus exemestane vs.
OFS plus tamoxifen was associated with a 4% absolute
improvement in 8-year DFS rate (HR 0.77; CI 95%,
0.67–0.90; p < .001), a 2.1% absolute improvement in
8-year DDFS rate (HR 0.80; CI 95%, 0.66–0.96; p = .02)
and a 0.1% non-significant gain in 8-year OS rate (HR
0.98; CI 95%, 0.79–1.22; p = .84) [7].
C. OFS plus exemestane reduced the risk of breast
cancer recurrence compared to tamoxifen alone
The SOFT trial showed a significant benefit in terms
of 5-year DFS rate for high-risk patients treated with
tamoxifen plus OFS rather than tamoxifen alone, with a
further improvement in the group who received exemes-
tane plus OFS [5]. Of note, in the SOFT trial the com-
parison between OFS plus exemestane and tamoxifen
alone became a secondary endpoint after the protocol
amendment allowing the joint analysis with the TEXT
trial, but the panellists still considered these data suffi-
cient to establish a superiority of OFS plus exemestane
to tamoxifen alone. Furthermore, subsequently to this
consensus, the updated analysis of the SOFT trial after
8 years of median follow-up confirmed a significant
benefit on DFS (HR 0.65; CI 95%, 0.53–0.81), DDFS (HR
0.73, 95% CI, 0.55–0.96) but not on OS (HR 0.85; CI
95%, 0.62–1.15) for OFS plus exemestane vs. tamoxifen
alone in the whole trial population [7].
D. The combination of OFS and tamoxifen may be an
alternative to OFS plus AIs for patients at
intermediate risk of breast cancer recurrence
For premenopausal patients with intermediate risk of
recurrence the panel estimates the benefit of exemestane
plus OFS over tamoxifen plus OFS to be only moderate,
even if it is difficult to classify intermediate-risk patients.
According to the composite risk score by Regan et al.
the BCFI benefit in this cohort is approximately 5% at
5 years [11]. Therefore, toxicities trade-off should be
carefully discussed while considering the available thera-
peutic options, and OFS plus tamoxifen might be the
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preferred combination for some women. Nevertheless,
some panellists believe that the intensity of adverse
events associated with these treatments are mainly related
to OFS itself, regardless the companion endocrine therapy,
thus recommending the proven most effective combination
(OFS plus exemestane), and not the one supposed to be
slightly better tolerated (OFS plus tamoxifen) also for
women at intermediate risk of recurrence.
Ovarian function suppression
The standard duration of adjuvant OFS for premenopausal
women with HR-positive EBC is 5 years, with LHRHa
therapy administered on a monthly basis
In this final section the panellists were asked to consider
OFS use in clinical practice, taking into account some
open questions on the routinely use of LHRHa therapies.
Most of the suggestions made by the panel were directly
dictated from SOFT and TEXT trials recommendations
on LHRHa administrations and treatment duration,
while others just mirror the best clinical practice. The
following statements were voted by the panellists and
gained positive consensus (Table 1):
A. Available data on OFS come from clinical trials in
which LHRHa therapy was administered on a
monthly basis
In both SOFT and TEXT trials ovarian suppression was
achieved by using triptorelin at a dose of 3.75 mg adminis-
tered by intramuscular injection every 28 days for 5 years
[5, 6]. Alternative ovarian ablation strategies allowed in
both studies were surgical oophorectomy and ovarian radi-
ation therapy. The optimal duration of LHRHa therapy
should also take into account side effects, patient prefer-
ences and pregnancy plans and some panellists believe that
the duration of OFS should be carefully evaluated for pa-
tients older than 50 years approaching natural menopause.
The efficacy and safety of a 3-monthly administration of
LHRHa have not been prospectively investigated and
should not be recommended.
B. Adjuvant endocrine treatment with LHRHa therapy
plus AIs may result in incomplete ovarian
suppression
A prospective sub-study of the SOFT trial (SOFT-EST)
aimed at evaluating estrogen levels in 112 patients re-
ceiving LHRHa plus tamoxifen or exemestane. Overall,
34.2% of patients receiving exemestane plus triptorelin
had at least one post-baseline beta-2-estradiol (E2) level
considered inconsistent with postmenopausal status [56].
Even considering these results, the panellists did not
recommend regular monitoring of follicle-stimulating hor-
mone (FSH), luteinizing hormone (LH) and E2 levels
during LHRHa treatment for analytical limits of the test and
cross-reactivity issues with tamoxifen administration. Never-
theless, particularly for premenopausal patients receiving
LHRHa plus AIs, FSH, LH and E2 levels should be
performed before the administration of AIs, to ensure effect-
ive OFS. A periodical monitoring through gynecological
ultrasound evaluation was also suggested by some panellists.
C. Potential predictive factors for suboptimal ovarian
suppression are high body mass index (BMI), no
prior chemotherapy, and low baseline FSH and LH
levels
According to the SOFT-EST trial results, the panellists
considered low baseline FSH and LH levels, high BMI
and no prior adjuvant chemotherapy as predictive fac-
tors potentially associated with suboptimal OFS [56].
D. Surgical oophorectomy could be an alternative to
LHRHa therapy, according to patients’ preferences.
Surgical oophorectomy may be considered in women
with severe side effects associated with OFS, no repro-
ductive desire or approaching natural menopause
E. LHRHa therapy should start preferably on the
second day of the menstrual cycle
Treatment with LHRHa should start in the early follicu-
lar phase (day 1–2 of the menstrual cycle) to increase the
likelihood of obtaining OFS in a short time and reduce
the risk of hyperstimulation or ovarian cysts formation
[57].
F. AIs should be administered at least 4 weeks after the
first injection of LHRHa therapy, when associated
with OFS
AIs must be used only in combination with OFS in
premenopausal women, since they cause negative hypo-
thalamic feedback and ovarian stimulation. Therefore,
their use should start only after an adequate period after
the first dose of LHRHa to ensure effective OFS.
G. Perimenopausal patients with chemotherapy-
induced amenorrhea should receive OFS if baseline
FSH and E2 levels are not in the postmenopausal
range
This statement was added after public discussion and
submitted for final vote. This recommendation should warn
clinicians that AIs are effective only in postmenopausal
women or in a setting of ovarian ablation. Therefore, in
case of chemotherapy-induced amenorrhea with FSH and
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E2 levels not clearly postmenopausal, exemestane must
only be used in combination with OFS. Nevertheless, in
case of ambiguity regarding the ovarian function (e.g. sub-
optimal ovarian suppression, incomplete compliance with
LHRHa), tamoxifen in combination of OFS should be pre-
ferred, regardless of the ovarian function status.
Conclusions
The ERA project represents an Italian perspective on
the role of OFS for the adjuvant treatment of premeno-
pausal patients with HR-positive EBC. Overall, in this
study, 31 Italian oncologists reached a positive consen-
sus over 28 statements related to prognostic groups,
therapeutic strategy and ovarian function suppression in
premenopausal patients with HR-positive EBC (Table 1).
The highest level of positive agreement was reached with
regard to the efficacy of OFS in addition to standard ad-
juvant endocrine therapy for premenopausal women
with HR–positive EBC at intermediate or high risk of re-
currence, with all the statements related to this topic ex-
ceeding the 97% of positive agreement. Of note, the
evidence-based approach of the Steering Committee in
defining the statements voted by the panellists may have
limited contrasting positions among the expert panel,
particularly when discussing objective results of the
SOFT and TEXT trials. Indeed, consensus was reached,
but with a lower level of agreement, on topics related to
the definition of prognostic factors and their relevance
in guiding therapeutic choices (> 84%) and ovarian func-
tion suppression in clinical practice (> 74%).
An update of the SOFT trial and the SOFT/TEXT joint
analysis presented after the conclusion of this consensus
study have recently confirmed the benefit of OFS in this
setting with additional follow-up [7]. In conclusion, the
SOFT and TEXT trials have changed the standard adjuvant
treatment of premenopausal patients with HR-positive
EBC, but the available treatment options require a careful
risk assessment and toxicities evaluation to ensure the
greatest clinical benefit for each patient.
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